The FDA granted priority review for trastuzumab deruxtecan in combination with pertuzumab for first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.

This guide was reviewed by a Business News Daily editor to ensure it provides comprehensive and accurate information to aid your buying decision. As technologies that capture and analyze data ...